AbbVie is acquiring Amgen-backed DJS Antibodies for $255m while Legend Holdings took part in a $56.6m series C round for VectorBuilder.


DJS Antibodies, the UK-based inflammatory disease-focused antibody therapy developer backed by Amgen, has been acquired by another pharmaceutical firm, AbbVie, for $255m. Amgen unit Amgen Ventures contributed to an $8.4m round for the company in late 2020.

Metaverse developer Translucia has purchased Infofed, the Thailand-based esports software platform that counts video game media group GameWith and event management portal operator EventPop as investors, for…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.